Neoplastic Condition Affecting Patents (Class 514/19.2)
  • Patent number: 10316076
    Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: June 11, 2019
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves
  • Patent number: 10206989
    Abstract: Isolated CDCA1-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce CDCA1-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: February 19, 2019
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yasuharu Nishimura, Yusuke Tomita, Ryuji Osawa
  • Patent number: 10098890
    Abstract: Disclosed herein are stabilized formulations of carfilzomib. The formulations exhibit increased storage stability relative to other formulations, and are simpler for health care providers to prepare and administer to patients.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: October 16, 2018
    Assignee: Cipla Limited
    Inventors: Harshad Kishore Shete, Pankaj Omprakash Pathak, Sarabjit Singh, Geena Malhotra
  • Patent number: 10080777
    Abstract: The invention provides for peptides from syndecan 4 and methods of use therefor. These peptides can inhibit ?6?4 integrin interaction with EGFR, thereby preventing tumor cell growth and tissue invasion, or inhibiting scarring and/or pathologic neovascularization.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: September 25, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Alan Rapraeger
  • Patent number: 10010581
    Abstract: The invention provides for peptides from syndecan 1 and methods of use therefor. These peptides can inhibit ?4?6 interaction with HER2, thereby preventing tumor cell growth and tissue invasion. The peptides can further be used to inhibit scarring and/or to inhibit pathologic neovascularization in a subject.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: July 3, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Alan Rapraeger
  • Patent number: 10000555
    Abstract: Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The related conjugates can target specific cell types to provide therapeutic benefit.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: June 19, 2018
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Toni Beth Kline
  • Patent number: 9629851
    Abstract: The current disclosure relates to pharmaceutical combinations and compositions useful in the treatment of certain types of cancer. The disclosure also relates to method of treatment these certain types of cancer. In particular, the disclosure relates to the combined use of inhibitors of ROCK and proteins of the MAPK/ERK-pathway in the treatment of KRAS-, NRAS- or BRAF-mutated cancer, in particular in NRAS mutated melanoma.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: April 25, 2017
    Assignee: STITCHING HET NEDERLANDS KANKER INSTITUT—ANTONI VAN LEEUWENHOEK ZIEKENHUIS
    Inventors: Daniel Simon Peeper, Marjon Antoinetta Smit, Celia Jill Vogel
  • Patent number: 9452215
    Abstract: The present invention is directed at bouvardin analogs arid related compounds for the treatment of disorders including cancer. Provided herein are bouvardin analogs and related compounds, pharmaceutical compositions and kits comprising at least one bouvardin analog or related compound, and methods for treating disorders including cancer. In some aspects the compounds inhibit translation elongation at the ribosome. The compounds are used in combination with radiation therapy or with known chemotherapeutic compositions.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: September 27, 2016
    Assignees: THE REGENTS OF THE UNIVERSITY OF COLORADO, SUVICA, INC.
    Inventors: Tin Tin Su, Mara N. Gladstone, Gan Zhang, Tarek Sammakia
  • Patent number: 9296681
    Abstract: The present invention provides novel cycloalkylmethylamine derivatives, and methods of preparing cycloalkylmethylamine derivatives. The present invention also provides methods of using cycloalkylmethylamine derivatives and compositions of cycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: March 29, 2016
    Assignee: REVIVA PHARMACEUTICALS, INC.
    Inventors: Laxminarayan Bhat, Seema Bhat
  • Patent number: 9199028
    Abstract: The present invention relates generally to compositions and methods for treating cancer patients with a poor prognosis, and to therapeutic modalities for improving prognosis by combating metastasis and abrogating chemoresistance in cancer cells. In particular, the invention relates to the role of white blood cells, i.e. neutrophils and neutrophil-like cells, in preventing the spread of cancer from a primary tumor to secondary locations in the body. The invention provides methods for reducing or delaying the spread of metastatic cancer cells in a patient at risk for metastatic tumor development, at risk for metastatic relapse, i.e. prophylactic methods, and treating patients suffering from metastatic tumors.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: December 1, 2015
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Zvi Granot, Robert Benezra
  • Patent number: 9074011
    Abstract: A composition for delivering cargo molecules across biological membranes is provided comprising (i) a peptide comprising consecutive amino acid residues having the sequence set forth in SEQ ID NO 1 for the transport of a cargo molecule across a biological membrane and (ii) the cargo molecule, wherein the cargo molecule is not a peptide comprising amino acid residues having the sequence set forth in SEQ ID NO 4. Methods of delivering cargo molecules across biological membranes are also provided. Methods of treating a tumor, cancer, a metabolic disorder, and a cardiovascular disorder are also provided.
    Type: Grant
    Filed: February 17, 2011
    Date of Patent: July 7, 2015
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventor: Ramon Parsons
  • Patent number: 9040662
    Abstract: In an aspect, the invention relates to compositions and methods for permeabilizing membranes of cells. In an aspect, the invention relates to compositions and methods for killing cells. In an aspect, the invention relates to compositions and methods of permeabilizing the membranes of cancer cells or microbial cells.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: May 26, 2015
    Assignee: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION
    Inventors: Annette Khaled, Rebecca Boohaker, Michael Lee, Jesus Perez Figueroa
  • Patent number: 9034827
    Abstract: The invention provides for peptides from syndecan 1 and methods of use therefor. These peptides can inhibit ?4?6 interaction with HER2, thereby preventing tumor cell growth and tissue invasion.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: May 19, 2015
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Alan Rapraeger
  • Patent number: 9034824
    Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: May 19, 2015
    Assignees: ONEDAY—BIOTECH AND PHARMA LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
  • Patent number: 9034828
    Abstract: The invention provides for peptides from syndecan 4 and methods of use therefor. These peptides can inhibit ?6?4 integrin interaction with EGFR, thereby preventing tumor cell growth and tissue invasion.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: May 19, 2015
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Alan Rapraeger
  • Patent number: 9023803
    Abstract: The present invention relates to cyclin D1-derived peptides for use in the improved treatment of cancer in a patient, particularly in the form of a combination therapy using a vaccine. Other aspects relate to the use of the peptides or a combination thereof as a diagnostic tool.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: May 5, 2015
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Harpreet Singh, Toni Weinschenk, Steffen Walter
  • Patent number: 9023802
    Abstract: Methods and compositions for immunotherapeutic treatment of prostate cancer are disclosed. Patients are treated with compositions comprising HLA-binding peptides derived from prostate-associated antigenic molecules, either with or without immunological adjuvants.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: May 5, 2015
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Hans Georg Rammensee, Stefan Stevanovic, Cecile Gouttefangeas, Toni Weinschenk, Peter Lewandrowski
  • Patent number: 9023337
    Abstract: Methods for enhancing or stimulating hematopoiesis including the step of administering Interleukin-12 (IL-12) to yield hematopoietic recovery in a mammal in need. Preferred methods include the step of administering IL-12 as an adjuvant therapy to alleviate the hematopoietic toxicities associated with one or more treatment regimens used to combat a disease state. Other methods include administering IL-12 to ameliorate various hematopoietic deficiencies. Still other methods are directed to uses of IL-12 for in-vivo proliferation of hematopoietic repopulating cells, hematopoietic progenitor cells and hematopoietic stem cells. Other disclosed methods are directed to uses of IL-12 for bone marrow preservation or recovery.
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: May 5, 2015
    Assignee: University of Southern California
    Inventors: Tingchao Chen, Yi Zhao, W. French Anderson
  • Patent number: 9023804
    Abstract: Methods and compositions for immunotherapeutic treatment of prostate cancer are disclosed. More specifically methods of treating patients with prostate cancer comprising administering compositions comprising HLA-binding peptides derived from prostate-associated antigenic molecules, either with or without immunological adjuvants, are disclosed.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: May 5, 2015
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Toni Weinschenk, Peter Lewandrowski, Hans Georg Rammensee, Stefan Stevanovic, Cecile Gouttefangeas
  • Patent number: 9017655
    Abstract: The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: April 28, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stuart Emanuel, Linda Engle, Ray Camphausen, Martin C. Wright, Ginger Chao Rakestraw, Marco Gottardis, Joan Carboni
  • Publication number: 20150110804
    Abstract: Compositions and methods for inhibiting, treating, and/or preventing a B-cell neoplasm are provided.
    Type: Application
    Filed: May 1, 2013
    Publication date: April 23, 2015
    Inventors: Andrei Thomas-Tikhonenko, Elaine Chung, James Psathas
  • Patent number: 9011867
    Abstract: The present invention relates to the use of a peptide comprising or essentially consisting of a sequence motif as shown in SEQ ID NO: 1 for the preparation of a medicament for the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS) or of Smoldering Multiple Myeloma (SMM). Moreover, the present invention relates to the use of an activated T-cell specifically recognizing the peptide of the present invention or an antigen presenting cell which specifically presents a peptide epitope of the present invention for the preparation of a medicament for the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS) or of Smoldering Multiple Myeloma (SMM). The present invention also relates to a method for the ex vivo manufacture of an activated T-cell of the present invention comprising the steps of: a) obtaining T-cells from a sample of a subject suffering from MGUS or SMM, b) contacting said T-cells with a peptide of the present invention, and c) collecting the activated T-cells.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: April 21, 2015
    Assignee: Ruprecht-Karls-Universitat Heidelberg
    Inventors: Michael Hundemer, Olaf Christensen
  • Publication number: 20150099693
    Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, the peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Application
    Filed: March 15, 2013
    Publication date: April 9, 2015
    Applicants: KAEL-GEMVAX CO., LTD., GEMVAX-AS
    Inventors: Sang Jae Kim, Kyun Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
  • Patent number: 8993721
    Abstract: Described herein is an isolated polypeptide which is capable of specifically targeting apoptotic cells undergoing apoptosis and consists of the sequence (I): Cys-X1-Val-Ala-Pro-X2 (I), wherein X1 is an amino acid with polar uncharged side chain and X2 is an amino acid with positive charged side chain. The isolated polypeptide of the present invention may be useful for detecting apoptotic cells, as well as detecting and imaging apoptotic cells in tumor tissue, apoptotic myocardial cells in myocardial infarction tissue, apoptotic nerve cells in stroke tissue, and arteriosclerosis site; the polypeptide is useful for targeted drug delivery thereto.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: March 31, 2015
    Inventors: Byung Heon Lee, In San Kim
  • Patent number: 8993524
    Abstract: The present invention is based on the seminal discovery that targeted immunomodulatory antibodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antibodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance. Such immune suppressive mechanisms include immunosuppressive cytokines (for example, Transforming growth factor beta (TGF-?) and regulatory T cells and/or immunosuppressive myeloid dendritic cells (DCs). By counteracting tumor-induced immune tolerance, the present invention provides effective compositions and methods for cancer treatment, optional in combination with another existing cancer treatment.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: March 31, 2015
    Assignee: The Johns Hopkins University
    Inventors: Atul Bedi, Rajani Ravi
  • Patent number: 8987266
    Abstract: The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: March 24, 2015
    Assignee: Genentech, Inc.
    Inventor: Somasekar Seshagiri
  • Patent number: 8987412
    Abstract: The present invention relates to peptides having one or more stable, internally-constrained HBS ?-helices, where the peptide is capable of interacting with Ras and related proteins.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: March 24, 2015
    Assignee: New York University
    Inventors: Paramjit Arora, Dafna Bar-Sagi, Anupam Patgiri, Kamlesh Yadav
  • Publication number: 20150080289
    Abstract: Disclosed are amphiphilic peptides. Also disclosed are methods of treating proliferative disease, bacterial infection, viral infection and fungal infection, endotoxin neutralization and a method of removing biofilm. Also disclosed is the use of the amphiphilic peptides.
    Type: Application
    Filed: August 29, 2013
    Publication date: March 19, 2015
    Inventors: Yi-Yan Yang, Zhan Yuin Ong
  • Patent number: 8980833
    Abstract: The present invention relates to novel cytotoxic molecules and their use for the treatment of cancer and other diseases.
    Type: Grant
    Filed: May 9, 2008
    Date of Patent: March 17, 2015
    Assignee: R&D-Biopharmaceuticals GmbH
    Inventor: Wolfgang Richter
  • Patent number: 8980269
    Abstract: A method for determining whether early stage cancer is present in a subject comprises detecting the expression level of GASP-1 in the subject by detecting the amount of GASP-1 peptide fragments present in a biological sample of the subject. Because cancer can be detected at an early stage, therapeutic targeting may be initiated before cancer reaches late stage (e.g., before the development of overt symptoms). A method for treating early stage cancer in a subject comprises administering to the subject an effective amount of a GASP-1 inhibitor to inhibit the progression of early stage cancer to late stage cancer. A Competitive ELISA capable of detecting GASP-1 peptide fragments at a concentration of less than 1 ng/ml was developed.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: March 17, 2015
    Assignee: Temple University of the Commonwealth System of Higher Education
    Inventors: Frank N. Chang, George P. Tuszynski
  • Patent number: 8980287
    Abstract: Use of intracytoplasmatic domain of Anaplastic Lymphoma Kinase (ALK) protein and/or a nucleic acid molecule encoding for the intracytoplasmatic domain of Anaplastic Lymphoma Kinase (ALK) protein, of any species, for the preparation of a medicament, preferably a vaccine, for the treatment and/or prevention of a tumor in a subject, preferably a lymphoma.
    Type: Grant
    Filed: September 25, 2008
    Date of Patent: March 17, 2015
    Inventors: Roberto Chiarle, Giorgio Inghirami, Guido Forni
  • Publication number: 20150071986
    Abstract: The present invention concerns a pharmaceutical composition comprising virtosomes isolated from non-dividing cells or the medium in which the cells are grown, for use in the inhibition of tumour growth and/or prevention of metastases.
    Type: Application
    Filed: May 29, 2014
    Publication date: March 12, 2015
    Applicant: The Foundation for Biomedical Research of La Paz University Hospital (FIBHULP)
    Inventors: Damián GARCIA-OLMO, Mariano Garcia-Arranz, Luz Vega Clemente, Peter Brian Gahan, Maurice Stroun
  • Patent number: 8975232
    Abstract: The present invention provides macrocyclic compounds of Formula (I): pharmaceutically acceptable salts thereof; and pharmaceutical compositions thereof, wherein R1, R2, R3, R4, RE, RF, RG, RH, RI, f, g, h, n, and m are as defined herein. The present invention further provides methods of synthesizing these macrocyclic compounds, and methods of their use and treatment. Certain aspects of the present invention relate to modulation of kinase activity, and in the treatment of kinase-associated diseases or disorders.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: March 10, 2015
    Assignee: President and Fellows of Harvard College
    Inventors: David R. Liu, Ralph E. Kleiner
  • Patent number: 8962569
    Abstract: Provided herein is tumor suppression composition and methods of making and using the same.
    Type: Grant
    Filed: May 25, 2011
    Date of Patent: February 24, 2015
    Assignees: The Regeants of the University of California, The United States of America as Represented by the Department of Veterans Affairs
    Inventors: Samuel S. Murray, Elsa J. Murray, Jeffrey C. Wang
  • Publication number: 20150051153
    Abstract: An environmentally sensitive membrane binding polypeptide, pH (low)-sensitive membrane peptide (pHLIP) has improved insertion kinetics balanced with solubility to selectively target acidic tissues.
    Type: Application
    Filed: July 13, 2011
    Publication date: February 19, 2015
    Inventors: Yana K. Reshetnyak, Oleg A. Andreev, Donald M. Engelman
  • Publication number: 20150050356
    Abstract: The present invention features methods for treating, stabilizing, preventing, and/or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy.
    Type: Application
    Filed: October 28, 2014
    Publication date: February 19, 2015
    Inventors: Neil P. DESAI, Patrick SOON-SHIONG, Vuong TRIEU
  • Patent number: 8957014
    Abstract: Methods to sensitize tumor cells to radiation therapy through the administration of an endothelin agonist such as the ETB agonist IRL1620.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: February 17, 2015
    Assignees: Spectrum Pharmaceuticals, Inc., The Board of Trustees of the University of Illinoise
    Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz
  • Patent number: 8951971
    Abstract: Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: February 10, 2015
    Assignees: Sanford-Burnham Medical Research Institute, The Regents of the University of California
    Inventors: Erkki Ruoslahti, Lianglin Zhang, Douglas Hanahan
  • Patent number: 8951975
    Abstract: Isolated peptides derived from SEQ ID NO: 42 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the afore-mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: February 10, 2015
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
  • Patent number: 8946171
    Abstract: The present invention relates to a pharmaceutical composition, comprising a cell cycle regulatory protein and/or an expressible nucleic acid coding for this in an amount suitable for immunization of an individual against carcinomas and the preliminary stages thereof and common auxiliary agents and/or to the use of a cell cycle regulatory protein and/or an expressible nucleic acid coding for this to immunize an individual against carcinomas and the preliminary stages thereof.
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: February 3, 2015
    Inventors: Magnus Von Knebel Doeberitz, Michael Linnebacher, Wolfgang Rudy
  • Patent number: 8945570
    Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: February 3, 2015
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
  • Patent number: 8946169
    Abstract: The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: February 3, 2015
    Assignee: NantBioScience, Inc.
    Inventors: Vuong Trieu, Neil P. Desai, Patrick Soon-Shiong
  • Publication number: 20150030700
    Abstract: This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa and velcade (bortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 29, 2015
    Inventors: Silvio Ernesto Perea Rodríguez, Yasser Perera Negrín, Arielis Rodríguez Ulloa, Jeovanis Gil Valdés, Yassel Ramos Gómez, Lila Rosa Castellanos Serra, Lázaro Hiram Betancourt Núñez, Aniel Sánchez Puente, Jorge Fernández de Cossio Dorta Duque, Boris Ernesto Acevedo Castro, Luis Javier González López, Vladimir Besada Pérez, Daniel Fernando Alonso, Daniel Eduardo Gomez
  • Patent number: 8940288
    Abstract: The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example IL-15 (SEQ ID NO: 5, 6), IL-2 (SEQ ID NO: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example IL-15Ra (SEQ ID NO: 7, 8), IL-2Ra (SEQ ID NO: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, SCID, AIDS, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or Lupus. The therapeutic complex of the invention surprisingly demonstrates increased half-life, and efficacy in vivo.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: January 27, 2015
    Assignee: University of Connecticut
    Inventors: Leo Lefrancois, Thomas A. Stoklasek
  • Patent number: 8940695
    Abstract: The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.
    Type: Grant
    Filed: January 6, 2006
    Date of Patent: January 27, 2015
    Assignee: Vegenics Pty Limited
    Inventors: Kari Alitalo, Taija Makinen
  • Publication number: 20150018278
    Abstract: The object of the invention is based on inhibiting specific phosphorylation on Thr248 and/or Thr250 residues of human transcription factor E2F4 to inhibit somatic endoreduplication processes in postmitotic cells which may be associated with various pathological conditions. The invention covers all currently known methods for the specific inhibition of protein phosphorylation (including the expression of mutant forms of E2F4 without Thr residues phosphorylated by p38MAPK) or methods developed in the future that may be applied to Thr-248 and/or Thr-250 residues of human transcription factor E2F4.
    Type: Application
    Filed: November 15, 2012
    Publication date: January 15, 2015
    Inventor: Jose Maria Frade Lopez
  • Publication number: 20150011458
    Abstract: The present invention relates to compounds of Formula I, IA, II, HA, III, or IHA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).
    Type: Application
    Filed: June 17, 2014
    Publication date: January 8, 2015
    Inventors: Jan-Eric Ahlfors, Khalid Mekouar
  • Patent number: 8920790
    Abstract: Methods for enhancing or stimulating hematopoiesis including the step of administering Interleukin-12 (IL-12) to yield hematopoietic recovery in a mammal in need. Preferred methods include the step of administering IL-12 as an adjuvant therapy to alleviate the hematopoietic toxicities associated with one or more treatment regimens used to combat a disease state. Other methods include administering IL-12 to ameliorate various hematopoietic deficiencies. Still other methods are directed to uses of IL-12 for in-vivo proliferation of hematopoietic repopulating cells, hematopoietic progenitor cells and hematopoietic stem cells. Other disclosed methods are directed to uses of IL-12 for bone marrow preservation or recovery.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: December 30, 2014
    Assignee: University of Southern California
    Inventors: Tingchao Chen, Yi Zhao, W. French Anderson
  • Patent number: 8920809
    Abstract: This invention provides, a recombinant polypeptide encoding a chimera. The chimera includes a DNase I fragment or a homologue thereof and a Cdt fragment or a homologue thereof. Further, the invention provides methods, utilizing the recombinant polypeptide encoding the chimera, such as a method for inhibiting the proliferation of a neoplastic cell, a method for treating a neoplastic disease in a human subject, a method for inhibiting or suppressing a neoplastic disease in a human subject, and a method for reducing the symptoms associated with a neoplastic disease in a human subject.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: December 30, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Joseph M. Dirienzo
  • Publication number: 20140378388
    Abstract: Embodiments herein provide a therapy for uterine leiomyomata (UL) in women using a fatty acid synthase (FAS) inhibitor. Additionally, an analysis method for evaluating the likelihood of women developing UL during their lifetime is provided.
    Type: Application
    Filed: September 4, 2014
    Publication date: December 25, 2014
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: CYNTHIA C. MORTON, STACEY L. EGGERT